GET THE APP

Possibilities of increasing the effectiveness of anti-Helicobacte | 59204
Journal of Hepatology and Gastrointestinal disorders

Journal of Hepatology and Gastrointestinal disorders
Open Access

ISSN: 2475-3181

Possibilities of increasing the effectiveness of anti-Helicobacter therapy regimens in Ukraine


16th Euro-Global Gastroenterology Conference

April 26-27, 2021 WEBINAR

Fadieienko G.D. and Nikiforova Ya.V

National Academy of Medical Sciences of Ukraine, Ukraine

Scientific Tracks Abstracts: J HepatolGastrointDis

Abstract :

The goal is to evaluate the effectiveness of various Anti-Helicobacter therapy (AHBT) regimens in Ukraine in order to select the most optimal treatment tactics. Object of Study and Methods: 624 patients were examined, with an average age of (50.89 ± 14.17) years. Female (338, 54.1%), Male (286, 45.9%). The most common nosology was chronic atrophic gastritis associated with Helicobacter pylori (НР) (501, 78.9%). Non-Investigated Dyspepsia (1, 0.2%), Functional Dyspepsia (2, 0.3%), Duodenal Ulcer (117, 18.4%), Gastric Ulcer (14, 2.2%). Most patients (449, 73.6%) did not receive primary therapy. Patients received different anti- Helicobacter therapy regimens: Dual (2, 0.3%), Triple (332, 52.2%), Quadruple (292, 45.9%), Sequential (0, 0.0%), Hybrid (0, 0.0%), Pylera (single capsule bismuth) (0, 0.0%), Other (10, 1.6%). Results and discussion: The most effective eradication scheme is Quadruple with the addition of Bismuth salts of tripotassium dicitrate (BTD) lasting 14 days (92.0%), as well as schemes with the inclusion of probiotics during AHBT with prolonged administration up to 4 weeks after the end of therapy (eradication efficiency is 90.6%). The effectiveness of Quadruple depending on the proton pump inhibitor (PPI) used was: Pantoprazole (92.0%), Esomeprazole (90.0%), Rabeprazole (89.9%), Omeprazole (78.6%) in therapeutic doses. Conclusions: Ways to increase the effectiveness of AHTB in Ukraine: adding BTC to therapy and duration of therapy for at least 10-14 days, using high doses of PPIs - Рpantoprazole, adding probiotics to treatment regimens.

Biography :

Senior researcher of the Department study of digestive diseases and their comorbidity with non-communicable diseases) Gi. L.T. Malaya Therapy National Institute of The National Academy Of Medical Sciences Of Ukraine. Publications. Author and co-author 157 scientific works in Ukrainian and foreign scientific issues (scientific articles, including DAC, SCOPUS, patents of Ukraine, certificate on scientific work, theses and reports). Scientific Organizations’ Membership Chair Ukrainian Gastroenterological Association Young Talent Group since 2016 Friends of YTG UEG since 2017.

Top